title: Palifermin in a hematopoietic stem cell transplant patient with osteonecrosis of the jaw.
abstract: This case report describes the use of palifermin in a multiple myeloma patient with a history of osteonecrosis of the jaw (ONJ) for the prevention of high-dose chemotherapy-induced mucositis. Following the day of autologous stem cell infusion, palifermin was discontinued secondary to adverse events. Specifically, palifermin-associated macroglossia seemed to exacerbate the pain localized in the oral cavity area affected by ONJ, necessitating escalated doses of narcotic analgesics. When contemplating palifermin as a mucosal protectant in a hematopoietic stem cell transplant patient with ONJ, a careful benefit-to-risk assessment is in order to ensure optimal effectiveness without undue harm.
authors.affiliation: Eugene Applebaum College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI 48201-2020, USA.
authors.forename: Leah A
authors.initials: LA
authors.lastname: Yageman
authors.forename: Simon M
authors.initials: SM
authors.lastname: Cronin
authors.forename: Edward
authors.initials: E
authors.lastname: Peres
authors.forename: Muneer H
authors.initials: MH
authors.lastname: Abidi
authors.forename: Rami B
authors.initials: RB
authors.lastname: Ibrahim
mesh_terms: D051523:Fibroblast Growth Factor 7 / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007568:Jaw; D052016:Mucositis / Q000139:chemically induced / Q000517:prevention & control; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D010020:Osteonecrosis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D019172:Transplantation Conditioning
chemical_list: D051523:Fibroblast Growth Factor 7